Brazilian guidelines for the management of brain-dead potential organ donors : the task force of the AMIB, ABTO, BRICNet, and the General Coordination of the National Transplant System by Westphal, Glauco Adrieno et al.
Westphal et al. Ann. Intensive Care          (2020) 10:169  
https://doi.org/10.1186/s13613-020-00787-0
RESEARCH
Brazilian guidelines for the management 
of brain-dead potential organ donors. 
The task force of the AMIB, ABTO, BRICNet, 
and the General Coordination of the National 
Transplant System
Glauco Adrieno Westphal1,2,3*, Caroline Cabral Robinson1, Alexandre Biasi Cavalcanti4, 
Anderson Ricardo Roman Gonçalves5,6, Cátia Moreira Guterres1, Cassiano Teixeira7,8, Cinara Stein1, 
Cristiano Augusto Franke7,9, Daiana Barbosa da Silva1, Daniela Ferreira Salomão Pontes10, 
Diego Silva Leite Nunes10, Edson Abdala11, Felipe Dal‑Pizzol12,13, Fernando Augusto Bozza14,15, 
Flávia Ribeiro Machado16, Joel de Andrade17, Luciane Nascimento Cruz1, Luciano Cesar Pontes de Azevedo18, 
Miriam Cristine Vahl Machado3, Regis Goulart Rosa1, Roberto Ceratti Manfro7,19, Rosana Reis Nothen19, 
Suzana Margareth Lobo20, Tatiana Helena Rech7, Thiago Lisboa7, Verônica Colpani1 and Maicon Falavigna1,21,22
Abstract 
Objective: To contribute to updating the recommendations for brain‑dead potential organ donor management.
Method: A group of 27 experts, including intensivists, transplant coordinators, transplant surgeons, and epidemi‑
ologists, joined a task force formed by the General Coordination Office of the National Transplant System/Brazilian 
Ministry of Health (CGSNT‑MS), the Brazilian Association of Intensive Care Medicine (AMIB), the Brazilian Association 
of Organ Transplantation (ABTO), and the Brazilian Research in Intensive Care Network (BRICNet). The questions were 
developed within the scope of the 2011 Brazilian Guidelines for Management of Adult Potential Multiple‑Organ 
Deceased Donors. The topics were divided into mechanical ventilation, hemodynamic support, endocrine‑metabolic 
management, infection, body temperature, blood transfusion, and use of checklists. The outcomes considered for 
decision‑making were cardiac arrest, number of organs recovered or transplanted per donor, and graft function/sur‑
vival. Rapid systematic reviews were conducted, and the quality of evidence of the recommendations was assessed 
using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Two expert 
panels were held in November 2016 and February 2017 to classify the recommendations. A systematic review update 
was performed in June 2020, and the recommendations were reviewed through a Delphi process with the panelists 
between June and July 2020.
Results: A total of 19 recommendations were drawn from the expert panel. Of these, 7 were classified as strong 
(lung‑protective ventilation strategy, vasopressors and combining arginine vasopressin to control blood pressure, 
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Introduction
Organ donation for transplantation is a complex process 
led by several health care professionals responsible for a 
sequence of actions and procedures that begin with iden-
tifying a potential organ donor and end with organ pro-
curement surgery and distribution. The progress of this 
process is essential to increase the deceased-donor pool, 
and to decrease the growing disparity between the num-
ber of patients on transplant waiting lists and the avail-
ability of organs [1, 2].
The organ donation process includes the identification 
of the potential donor, diagnosis of brain death, family 
support and interview, evaluation of donor eligibility cri-
teria, clinical management of the potential organ donor, 
and organ procurement and distribution [2, 3]. Given 
the marked clinical instability that occurs in patients 
who progress to brain death, the application of poten-
tial donor-management strategies aiming at hemody-
namic stabilization is crucial to avoid loss of organs due 
to hypoperfusion or loss of donors due to cardiac arrest. 
Also, the control of ventilatory support, body tempera-
ture, and endocrine-metabolic functions contributes to 
improving the quality of organs and clinical outcomes in 
transplant recipients [1, 2, 4, 5].
Despite the lack of evidence on some aspects of the 
clinical management of potential organ donors, the 
recommendations presented in this guideline intend 
to promote a general approach to mitigate the dis-
parity between supply and demand of organs for 
transplantation.
Objective
To provide recommendations to guide the clinical man-
agement of brain-dead potential organ donors aiming to 
reduce the rate of cardiac arrest of the potential donor 
and to improve organ viability for transplantation.
Method
The present document provides a partial update on the 
2011 Brazilian Guidelines for Management of Adult 
Potential Multiple-Organ Deceased Donors [6–8]. 
The working group consisted of physicians, nurses, 
pharmacists, physical therapists, epidemiologists, meth-
odologists, and transplant system managers. The contri-
butions of each participant are shown in Additional file 1, 
and the respective conflict-of-interest disclosures are 
shown in Additional file 2.
The target audience of this guideline is health care pro-
fessionals, especially physicians and nursing staff work-
ing in adult ICUs and emergency departments, who are 
involved in the care of adult individuals with known or 
suspected brain death.
The clinical issues addressed by the guideline were 
defined by coordinators of the working group and the 
methodologists in a face-to-face meeting held in March 
2016, after reviewing the recommendations of the 2011 
Brazilian Guidelines for Management of Adult Potential 
Multiple-Organ Deceased Donors [6–8]. The issues were 
prioritized according to the perception of their impact on 
medical management and variability in clinical practice 
and divided into the following major topics: (1) ventila-
tory support; (2) hemodynamic support; (3) endocrine, 
metabolic and nutritional management; (4) specific 
aspects that include infection and sepsis, red blood cell 
transfusion, and body temperature control; and (5) goal-
directed therapy. For each clinical issue, operational 
questions were developed and framed using the PICO 
(population-intervention-comparison-outcome) format. 
The population of interest consists of potential organ 
donors with known or suspected brain death [3], hereaf-
ter referred to as potential donors. The outcomes consid-
ered for decision-making were cardiac arrest, the number 
of organs recovered or transplanted per donor, and graft 
function or graft survival.
For each clinical issue, rapid systematic reviews [9, 10] 
were conducted using the following search strategy: (1) 
Review of the reference lists of Brazilian guidelines [6–8] 
and the Society of Critical Care Medicine (SCCM) [11] 
statement on the management of the potential organ 
donor; (2) Review of related topics in the DynaMed and 
UpToDate databases; and (3) PubMed search focusing 
on systematic reviews and clinical trials published until 
October 2016 and until January 2017. Quality of evidence 
was assessed using the Grading of Recommendations 
antidiuretic hormones to control polyuria, serum potassium and magnesium control, and antibiotic use), 11 as weak 
(alveolar recruitment maneuvers, low‑dose dopamine, low‑dose corticosteroids, thyroid hormones, glycemic and 
serum sodium control, nutritional support, body temperature control or hypothermia, red blood cell transfusion, and 
goal‑directed protocols), and 1 was considered a good clinical practice (volemic expansion).
Conclusion: Despite the agreement among panel members on most recommendations, the grade of recommenda‑
tion was mostly weak. The observed lack of robust evidence on the topic highlights the importance of the present 
guideline to improve the management of brain‑dead potential organ donors.
Keywords: Guidelines, Organ donation, Intensive care, Brain death, GRADE
Page 3 of 15Westphal et al. Ann. Intensive Care          (2020) 10:169  
Assessment, Development, and Evaluation (GRADE) sys-
tem [12].
The recommendations were prepared and submitted to 
two face-to-face expert panels held in November 2016, 
and February 2017. For each recommendation, the direc-
tion of the course of action was discussed (whether to 
perform or not to perform the proposed action), and the 
strength of the recommendation was classified as strong 
or weak according to the GRADE system [12]. After the 
last panel meeting, a new systematic search covering the 
period from October 2016 to May 2020 was carried out 
to identify new evidence that could potentially modify 
the recommendations. From June to July 2020, a Delphi 
process was performed with the panelists to present the 
results of the literature update and review the direction 
and strength of the recommendations.
Results
A total of 19 recommendations were drawn from the 
expert panel. Of these, 7 were classified as strong, 11 as 
weak, and 1 was considered as good clinical practice. 
Table 1 shows a summary of the recommendations. Fig-
ure 1 presents graphically the flow of the recommenda-
tions along the clinical management. Additional file  3 
provides a checklist with the main recommendations 
with a positive direction of action to assist in bedside 
monitoring of clinical goals related to the recommenda-
tions and in the application of the management strategies. 
Ventilatory support
1. We recommend using a lung-protective ventilation 
strategy in all potential donors (low level of evidence, 
strong recommendation).
Summary of evidence In potential donors, an initially 
normal or near-normal lung function  (PaO2/FiO2 ≥ 300) 
may deteriorate due to common complications in criti-
cal patients, such as pulmonary contusion, lung injury 
following blood transfusion, pneumonia, atelectasis, 
and mechanical ventilation-related iatrogenic injuries 
[13–18]. In addition, approximately 30–45% of poten-
tial donors develop acute respiratory distress syndrome 
(ARDS;  PaO2/FiO2 < 300), and only 15–20% of the lungs 
are suitable for transplantation at the end of the procure-
ment process [13, 15, 17]. The lung-protective ventilation 
strategy in potential donors with normal lungs and the 
apnea testing performed with continuous positive airway 
pressure (CPAP) have been associated with an increase in 
eligibility for lung donation [18–20].
Remarks The protective ventilation strategy for healthy 
lungs consists of the combination of a tidal volume of 
6–8  mL/kg and PEEP of 8–10-cm  H2O. To promote 
adequate blood oxygenation,  FiO2 and PEEP must be 
adjusted to obtain a  SaO2 > 90%. To avoid atelectasis, 
the apnea test with 10 cm  H2O CPAP can be performed 
using a closed-circuit system in potential donors with 
preserved lungs who are candidates for lung procure-
ment, or even when hypoxemic respiratory failure is 
present. Also, the same procedure can be considered on 
those who have failed the test due to hypoxemia after 
disconnection.
2. We suggest not using alveolar recruitment maneu-
vers routinely in potential donors (very low level of 
evidence, weak recommendation).
Summary of evidence Although alveolar recruitment 
maneuvers have been suggested for the ventilatory 
management of organ donors with lung injury  (PaO2/
FiO2 < 300) [13–16, 18, 20], and these maneuvers could 
reduce hypoxemia after apnea testing, contributing to 
increasing the viability of pulmonary grafts [14–18, 20], 
a randomized clinical trial showed unfavorable outcomes 
in critically ill patients [21]. Besides, no randomized stud-
ies have demonstrated their efficacy in the population of 
potential donors.
Remarks Performing alveolar recruitment maneuvers 
in hemodynamically stable potential donors is probably 
feasible in units with experience in the management of 
ARDS. In cases of hypoxemia refractory to the lung-pro-
tective ventilation strategy, however, alveolar recruitment 
maneuvers should not be performed routinely. Their use 




3. We recommend performing initial volemic expan-
sion in hemodynamically unstable potential donors 
with hypovolemia or responsive to fluids according 
to fluid responsiveness assessment (good clinical 
practice).
4. We recommend administering norepinephrine or 
dopamine to control blood pressure in potential 
donors who remain hypotensive after volemic expan-
sion (very low level of evidence, strong recommenda-
tion).
Summary of evidence Potential donor hypotension is 
associated with a higher incidence of postoperative liver 
graft dysfunction and longer hospital stay in liver trans-
plant recipients [22, 23]. Targeting a mean arterial pres-
sure (MAP) ≥ 65  mm Hg has also been associated with 
reduced occurrence of cardiac arrest in potential donors 
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Table 1 Summary of recommendations
Recommendations Level of evidence Grade of recommendation Practical considerations
Ventilatory support
 1. We recommend using a lung‑protective venti‑
lation strategy in all PDs
Low Strong Vt between 6 and 8 mL/kg of predicted body weight 
and PEEP of 8–10‑cm  H2O
Adjust  FiO2 and PEEP to obtain  SaO2 > 90%
Perform apnea testing with CPAP
 2. We suggest not using ARM routinely in PDs Very low Weak ARM can be considered if there is refractory hypox‑
emia in hemodynamically stable PDs
Hemodynamic support
 3. We recommend performing initial volemic 
expansion in hemodynamically unstable PDs 
with hypovolemia or responsive to fluids 
according to fluid responsiveness assessment
Good clinical practice Initial volume expansion with 30 mL/kg of crystal‑
loids
Assess fluid status and responsiveness for additional 
fluid replacement
Preferably use dynamic parameters
Neutral or negative fluid balance after achieving 
hemodynamic stability
 4. We recommend administering norepineph‑
rine or dopamine to control blood pressure 
in PDs who remain hypotensive after volemic 
expansion
Very low Strong Start adrenergic vasopressors to obtain a 
MAP ≥ 65 mm Hg
Dopamine is the vasopressor of choice when there 
is bradycardia
Consider the potential arrhythmogenic effect of 
dopamine, which implies the risk of PD loss due to 
cardiac arrest
 5. We suggest not using low‑dose dopamine for 
renal protection in PDs
Very low Weak Consider the potential arrhythmogenic effect of 
dopamine, which implies the risk of PD loss due to 
cardiac arrest
Endocrine and electrolyte management
 6. We recommend combining AVP in PDs receiv‑
ing norepinephrine or dopamine
Low Strong Combine AVP (1 IU bolus + 0.5–2.4 IU/h) with norepi‑
nephrine or dopamine
 7. We recommend administering AVP or DDAVP 
to control polyuria in PDs with diabetes 
insipidus
Low Strong AVP if vasopressors are required.
DDAVP (1–2‑µg IV 2–4 h) if vasopressors are not 
required
 8. We suggest combining low‑dose corticos‑
teroids in PDs receiving norepinephrine or 
dopamine
Low Weak Combine 300 mg IV/day in PDs with norepinephrine 
or dopamine
 9. We suggest not using thyroid hormones 
routinely in PDs
Very low Weak There are no hemodynamic benefits
They can be considered if prolonged management 
is required
 10. We suggest performing glycemic control in 
PDs
Very low Weak Administer insulin to achieve a glucose level of 
140–180 mg/dL
Monitor blood glucose at least every 6 h
 11. We suggest maintaining serum sodium 
levels < 155 mEq/dL in PDs
Very low Weak Correct water deficit with hypotonic fluids
Correct hypovolemia
 12. We recommend maintaining serum potas‑
sium levels between 3.5 and 5.5 mEq/L in PDs
Very low Strong
 13. We recommend maintaining serum magne‑
sium levels > 1.6 mEq/L in PDs
Very low Strong
Other aspects
 14. We suggest maintaining nutritional support in 
PDs if well tolerated
Very low Weak
 15. We recommend using antibiotics in PDs with 
infection or sepsis
Low Strong Maintain appropriate antibiotic therapy in the donor 
for at least 24 h
Collect cultures from different sites in all donors
 16. We suggest maintaining body temperature 
above 35 °C in hemodynamically unstable PDs
Very low Weak Monitor core temperature
Prevent and treat hypothermia in PDs receiving 
vasoactive amines
 17. We suggest inducing hypothermia (34–35 °C) 
in PDs without hemodynamic instability
Low Weak Monitor core temperature
Induce hypothermia by applying ice packs in PDs not 
receiving vasoactive amines
 18. We suggest transfusing packed red blood cells 
in PDs with hemoglobin levels < 7 g/dL
Very low Weak
 19. We suggest using goal‑directed protocols dur‑
ing the management of PDs
Very low Weak Monitor care using evidence‑based clinical goal‑
directed checklists
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[22, 24]. Intravascular volume expansion guided by ven-
tricular filling pressures or respiratory pulse pressure 
variation (PPV) in hemodynamically unstable potential 
donors is associated with faster recovery of renal graft 
function and reduced circulating levels of inflammatory 
cytokines [22, 25]. A randomized trial detected no differ-
ence between usual fluid management or fluid manage-
ment directed by a PPV and cardiac index. On the other 
hand, there was a trend toward an increase in the number 
of organs transplanted per donor among unstable poten-
tial donors responsive to fluids (p = 0.059) [26].
Conversely, avoiding fluid overload after the initial vol-
ume resuscitation to stabilize blood pressure seems to 
be beneficial. This approach is associated with a greater 
number of organs transplanted per donor and a greater 
number of lungs transplanted without reducing the num-
ber of other donated organs or impairing survival in the 
heart, liver, pancreas, or kidney transplant recipients [19, 
27–29].
If hypotension persists after adequate volume resusci-
tation, adrenergic vasopressors should be used to achieve 
adequate blood-pressure levels [30]. There is no dif-
ference in clinical outcomes in studies comparing nor-
epinephrine and dopamine [31–33]. Disruption of vagal 
activity secondary to brain death may result in atropine-
refractory bradycardia. In these cases, adrenergic drugs 
Table 1 (continued)
PD: potential donor; Vt: total volume; PEEP: positive-end expiratory pressure;  SaO2: arterial oxygen saturation; CPAP: continuous positive airway pressure; ARM: 
alveolar recruitment maneuver; MAP: mean arterial pressure; AVP: arginine-vasopressin; DDAVP: 1-deamino-8-d-arginine-vasopressin; IV: intravenous
Fig. 1 Flow of the recommendations
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as isoproterenol, epinephrine, and dopamine have been 
suggested as positive chronotropic agents to treat brad-
ycardia in potential donors. Considering the predomi-
nance of noradrenaline action on alpha-1 receptors, its 
infusion usually occurs without significant increase in 
heart rate. Hence, dopamine or epinephrine may be more 
convenient for the treatment of hypotension due to a 
positive chronotropic effect [6, 34, 35].
Remarks Obtaining an MAP ≥ 65  mm Hg as a blood-
pressure target contributes to the perfusion of organs 
that are intended to be preserved for transplantation 
[22–24]. Hypovolemia is very frequent in potential organ 
donors and should be considered when hypotension is 
present. The initial infusion of crystalloids (e.g., 30 mL/
kg) in potential donors who are hypovolemic or respon-
sive to fluids (when any fluid responsiveness assessment 
parameter is already available) contributes to blood-pres-
sure control by improving tissue perfusion [24–26].
Conversely, fluid overload should be avoided [19, 
27–29]. Assessment of fluid responsiveness with static 
variables (e.g., central venous pressure—CVP) and/or 
dynamic parameters (e.g., PPV) can be used to guide 
volume replacement, helping to prevent fluid overload. 
Dynamic parameters can more accurately discriminate 
between responsive and unresponsive individuals [30–
38]. Once hemodynamic stability is achieved, strategies 
aimed at neutral fluid balance may be more beneficial 
[19, 27–29].
If the blood-pressure target is not achieved with the ini-
tial volume expansion, norepinephrine or dopamine infu-
sion should be started immediately. The use of dopamine 
is likely advantageous for cases of bradycardia with signs 
of low cardiac output [6, 34, 35], but the arrhythmogenic 
potential of dopamine should be considered [39].
5. We suggest not using low-dose dopamine for renal 
protection in potential donors (very low level of evi-
dence, weak recommendation).
Summary of evidence A cohort study of 93 heart trans-
plant recipients showed that pretreatment with low-dose 
dopamine (4 μg/kg/min) in heart donors was associated 
with higher graft survival 3  years after transplantation 
(87.0 vs. 67.8%, p < 0.03) [40]. A randomized-controlled 
trial of 264 organ donors reported that the administra-
tion of low-dose dopamine reduced the need for hemodi-
alysis in recipients (OR 0.54; 95% CI 0.35–0.83), but with 
no benefits for kidney graft survival after 3  years [41]. 
In the 5-year follow-up analysis of 487 renal transplant 
recipients from the same trial, the researchers failed to 
show a significant advantage of dopamine administration 
in potential donors to long-term kidney graft survival, 
although time of dopamine infusion and graft failure 
were exposure-related (HR 0.96; 95% CI 0.92–1.00, per 
hour) [42]. The same group reported that low-dose dopa-
mine did not negatively affect the short- or long-term 
outcomes after liver transplants [43].
Remarks Although the administration of low-dose 
dopamine in potential donors reduces the need for multi-
ple dialysis sessions, the long-term benefits for heart and 
kidney graft survival are unclear. The panel considered 
the potential arrhythmogenic effect of dopamine, which 
may imply a greater risk of loss of potential donors due to 
cardiac arrest before organ procurement.
Endocrine and electrolyte management
Hormones
6. We recommend combining arginine vasopressin 
(AVP) in potential donors receiving norepinephrine 
or dopamine to control blood pressure (low level of 
evidence, strong recommendation).
Summary of evidence The use of AVP in brain-dead 
potential donors contributes to reducing the need for 
adrenergic vasopressors and is associated with a lower 
incidence of cardiovascular deterioration and cardiac 
arrest [44–48], in addition to contributing to the control 
of plasma hyperosmolarity [46]. AVP infusion allows, in 
some cases, complete discontinuation of adrenergic vaso-
pressors without causing adverse effects on the function 
of organs transplanted [48, 49]. Finally, AVP infusion 
seems to be associated with a greater number of donated 
organs and a lower rate of graft refusal due to organ dys-
function [45].
Remarks The administration of an initial 1  IU AVP 
bolus followed by infusion of 0.5 IU/h to 2.4 UI/h helps 
to maintain blood pressure in potential donors requiring 
vasopressors, and contributes to the control of polyuria 
and normovolemia in the presence of diabetes insipidus 
[44–46, 48, 49]. AVP should be started at the same time 
of adrenergic vasopressor infusion.
7. We recommend administering AVP or 1-deam-
ino-8-d-arginine vasopressin (DDAVP) to control 
polyuria in potential donors with diabetes insipidus 
(low level of evidence, strong recommendation).
Summary of evidence The analysis of the database of a 
randomized clinical trial that evaluated 487 renal graft 
recipients showed better control of daily urine output 
(p < 0.001) and a lower need for fluids in the DDAVP 
group (p < 0.001). DDAVP was associated with improved 
renal graft survival (85.4% vs. 73.6%, p = 0.003) after 
2 years, with no differences in acute rejections (OR 1.32; 
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95% CI 0.70–2.49) or delayed graft function (OR 0.97; 
95% CI 0.57–1.65) [50].
Remarks DDAVP acts exclusively on V2 receptors and 
is indicated to control polyuria (urine output > 4  mL/
kg/h) in potential donors with diabetes insipidus who 
maintain adequate blood pressure without adrenergic 
vasopressors. AVP is preferred to control polyuria in 
potential donors with diabetes insipidus who need adren-
ergic vasopressors. The combination of AVP and DDAVP 
may be considered in refractory cases [51]. Although the 
intranasal route is feasible, DDAVP should preferably be 
administered intravenously, at a dose of 1–2  µg every 
2–4  h [8, 13, 15], until a urine output < 4  mL/kg/h has 
been achieved [50–53].
8. We suggest using low-dose corticosteroids in poten-
tial donors receiving norepinephrine or dopamine to 
control blood pressure (low level of evidence, weak 
recommendation).
Summary of evidence A small retrospective study 
reported that administration of 15-mg/kg methylpred-
nisolone was associated with higher  PaO2/FiO2 values 
(p = 0.01) and a greater number of lungs transplanted 
(p < 0.01) [54]. Conversely, a before-and-after study 
comparing 15-mg/kg methylprednisolone with 300-mg 
hydrocortisone found no difference in the oxygenation 
and hemodynamic stability of the potential donor or in 
the number of organs transplanted [55]. A recent small 
randomized-controlled trial showed that a single dose 
of 15  mg/kg/day of methylprednisolone administered 
to the potential organ donor may negatively affect the 
graft function by increasing the antigenicity of the kid-
neys before transplantation. This negative effect was not 
noticed among brain-dead donors who received 15 mg/
kg/day of methylprednisolone followed by 100 mg every 
2  h until organ harvesting [56]. Eleven randomized-
controlled trials analyzed in a systematic review did not 
support the use of high-dose corticosteroids in the man-
agement of potential donors [57]. On the other hand, a 
randomized multicenter cluster study including 259 
individuals compared the administration of low-dose 
hydrocortisone (300  mg/day) with no corticosteroids. 
The doses (p = 0.03) and duration of infusion (p < 0.001) 
of vasopressors were lower in the intervention group, and 
the complete vasopressor withdrawal was 4.7 times more 
frequent in the corticosteroid group [58].
Remarks Despite conflicting evidence, the use of corti-
costeroids is of low cost and a low risk to potential donors 
and may have a positive effect on hemodynamic out-
comes; therefore, their use is indicated in these patients. 
Current evidence does not suggest ventilatory or hemo-
dynamic benefits associated with corticosteroid therapy 
at high doses compared with low doses (i.e., 100 mg every 
8 h). Higher doses should be avoided.
9. We suggest not using thyroid hormones routinely in 
potential donors (very low level of evidence, weak 
recommendation).
Summary of evidence Administration of thyroid hor-
mones in potential donors did not add any benefit, such 
as a reduction in vasopressor use, an increase in cardiac 
index, or an increase in organ procurement for trans-
plantation [59–65]. Observational studies had suggested 
an increase in heart procurement, which was not con-
firmed in randomized clinical trials [66, 67], even in 
brain-dead organ donors with hemodynamic instability 
and/or impaired cardiac function [68, 69].
Remarks Brain death is associated with a drop in circu-
lating thyroid hormone levels, which could contribute to 
hemodynamic instability; however, there is no evidence 
to support the use of thyroid hormones in potential 
donors, given their costs and risks.
 10. We suggest performing glycemic control in poten-
tial donors (very low level of evidence, weak rec-
ommendation).
Summary of evidence Four observational studies eval-
uated the effect of potential donor hyperglycemia on 
post-transplant pancreatic function [70–73]. One study 
showed a correlation between donor blood glucose 
immediately before organ retrieval and HbA1C 1  year 
after transplantation [73], and another study found an 
association between hyperglycemia and graft loss (HR 
1.4; p = 0.03) [74]. Two studies showed no association 
between potential donor blood glucose and post-trans-
plant pancreatic graft function [70–72]. One obser-
vational study found an association between glycemic 
control and creatinine of the potential donor before 
organ retrieval [75]. Conversely, there is no evidence that 
hyperglycemia is associated with liver graft dysfunction 
[76]. A study of 1611 potential donors reported that a 
glucose level < 180 mg/dL was an independent predictor 
of four or more organs transplanted per donor (OR 1.35; 
95% CI 1.01–1.82) [77]. A set of potential donor care 
measures, including glycemic control, was associated 
with achieving ≥ 3 organs transplanted per donor (OR 
1.9; 95% CI 1.35–2.68), but it was not possible to assess 
the isolated effect of glycemic control [78].
Remarks Very-low-quality evidence suggests that a 
glucose level < 180  mg/dL is associated with a greater 
number of organs transplanted. Blood glucose should be 
monitored in all potential donors at least every 6 h, tar-
geting levels of 140–180 mg/dL, and intravenous insulin 
infusion can be used to this end.
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Electrolytes
 11. We suggest maintaining serum sodium levels below 
155 mEq/dL in potential donors (very low level of 
evidence, weak recommendation).
Summary of evidence. Five descriptive observational 
studies were identified (n = 5733), which evaluated 
only graft viability/function. In four of these studies 
(n = 5545), there was no negative effect of donor hyper-
natremia above 155 mEq/L on liver or heart graft func-
tion [79–82]. In only one study (n = 188), hypernatremia 
was associated with more cases of early graft loss [83]. 
Some authors have suggested that deceased-donor 
hypernatremia may be a factor for worse prognosis of 
graft function, but these findings have not been univer-
sally confirmed [79–85]. Changes in natremia may reflect 
inadequate volume management, especially in the pres-
ence of diabetes insipidus, one of the reasons for its cor-
rection [11].
Remarks Hypernatremia is often associated with hypo-
volemia, and should be controlled with volume expan-
sion, replacement of hypotonic fluids, and control of 
polyuria with AVP or DDAVP. Serum sodium should be 
monitored, targeting levels < 155 mg/dL.
 12. We recommend maintaining serum potassium lev-
els between 3.5 and 5.5 mEq/L in potential donors 
(very low level of evidence, strong recommenda-
tion).
Summary of evidence There are no studies that directly 
evaluate the effect of hyper- or hypokalemia in poten-
tial donors. A comparison of potassium levels in ICU 
patients showed that hyperkalemia was more common 
in patients who died (9.2% vs. 0.9%, p < 0.001) and that 
serum potassium concentration could be a predictor of 
death in critically ill patients [86].
Remarks Despite the absence of studies directly evalu-
ating the effects of potential donor serum potassium 
levels, potassium is a determining factor in the resting 
potential of electrically sensitive cells. Changes in potas-
sium levels are related to cardiac arrhythmias and may 
compromise the management of potential donors. Potas-
sium levels should be monitored, and usual correction 
measures should be implemented, targeting serum levels 
between 3.5 and 5.5 mEq/L.
 13. We recommend maintaining serum magnesium 
levels above 1.6  mEq/L in potential donors (very 
low level of evidence, strong recommendation).
Summary of evidence Studies on the influence of serum 
magnesium levels were found in critically ill patients, 
but none in potential donors [87–92]. Two observa-
tional studies and one randomized study identified 
an association between hypomagnesemia and higher 
mortality in critically ill patients [87, 88, 91], in addi-
tion to a greater likelihood of QT interval prolongation 
(OR 42.8; 95% CI 14.5–126.2) [88]. This association of 
hypomagnesemia with mortality was reinforced in a sys-
tematic review [89]. In addition to being arrhythmogenic, 
hypomagnesemia appears to be associated with non-
recovery of renal function in patients with acute kidney 
injury (70% vs. 31%, p = 0.003) [92].
Remarks Hypomagnesemia is associated with cardiac 
arrhythmias and worse prognosis in critically ill patients, 
with no direct evidence in brain-dead potential donors. 
However, this is a low-cost procedure, and in the ICU 
setting, routine monitoring until normalization of mag-
nesium levels is a common practice, which may be ben-
eficial for potential donors. Magnesium levels should be 
monitored, and magnesium sulfate should be adminis-
tered, as usual, targeting serum levels above 1.6 mEq/L.
Other aspects of potential donor management
Nutritional support
 14. We suggest maintaining nutritional support in 
potential donors if well tolerated (very low level of 
evidence, weak recommendation).
Summary of evidence Although there is no evidence on 
nutritional support, different guidelines recommend con-
tinuing nutritional support of the donor in the absence 
of contraindications [7, 9, 51]. Possible benefits include 
increased liver glycogen reserves, which could posi-
tively influence the liver graft [93, 94], and maintenance 
of intestinal mucosal trophism, which could reduce the 
potential for bacterial translocation.
Remarks For brain-dead individuals requiring ICU 
management for prolonged periods (e.g., brain-dead 
pregnant women; prolongation of the diagnostic pro-
cess or the family decision for donation), it is reasonable 
that energy expenditure should be estimated or meas-
ured [95], considering that baseline energy expenditure 
is 15–30% lower in brain-dead individuals than in other 
critically ill patients [96]. Thus, in individuals already 
receiving full nutritional support, energy intake may be 
reduced once brain death is established. A minimum 
energy intake (e.g., 500  kcal) could be considered in 
potential donors who had not been on enteral feeding 
before brain death was diagnosed, taking into account its 
potential benefit in the maintenance of intestinal mucosal 
trophism. However, it does not seem appropriate to start 
enteral feeding when the organs are likely to be har-
vested within a short period or in the presence of any of 
the usual contraindications to initiate/maintain enteral 
feeding (e.g., gastrointestinal tract obstruction, ileus, 
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vomiting/aspiration of gastric contents, severe hemody-
namic instability, and high doses of vasopressors).
Infection and sepsis
 15. We recommend using antibiotics in potential 
donors with infection or sepsis (low level of evi-
dence, strong recommendation).
Summary of evidence Different observational studies 
evaluated the transmission of bacterial infection in organ 
donors with culture-proven infection. The most com-
monly observed microorganisms were Staphylococcus 
aureus, Streptococcus sp., Klebsiella sp., and Acinetobac-
ter baumannii. Bacterial transmission is rarely observed 
[97–104], provided that donors with evidence of infec-
tion receive appropriate antibiotic therapy [97–102, 105, 
106]. The duration of donor antibiotic therapy ranged 
from 24 to 96  h in different studies [97, 99, 102, 105]. 
Also, different authors have reported maintaining the 
same antibiotics administered to the donors in the trans-
plant recipients, for periods ranging from 7 to 14  days 
[98, 100, 105, 106]. The presence of donor infection had 
no impact on the survival of grafts or transplant recipi-
ents [97–102, 105, 106].
Remarks The risk of transmission of bacterial infection 
from organ donors to recipients is low, and donor infec-
tion does not appear to negatively affect outcomes. The 
risks are lower with appropriate antibiotic therapy in the 
donor for at least 24  h, followed by maintenance of the 
antibiotic in the recipient for 7–14  days [97–102, 105, 
106]. Some donors have subclinical bacteremia at the 
time of organ procurement; therefore, cultures should be 
collected from blood and different sites in all donors, and 
the recipient antibiotic therapy should be directed by the 
results of culture [99, 107–110].
Body temperature control
 16. We suggest maintaining body temperature above 
35  °C in hemodynamically unstable potential 
donors (very low level of evidence, weak recom-
mendation).
 17. We suggest inducing moderate hypothermia (34–
35  °C) in potential donors without hemodynamic 
instability (low level of evidence, weak recommen-
dation).
Summary of evidence Delayed renal graft function 
was evaluated in a randomized-controlled trial that 
compared hypothermia (34–35  °C) versus usual man-
agement (36.5–37.5 °C) in 370 potential donors without 
hemodynamic instability. The main result was a reduc-
tion in delayed renal graft function among recipients 
(OR 0.62; 95% CI 0.43–0.92). There was no differ-
ence in the number of organs transplanted per donor, 
adverse events, or cardiac arrest [111]. Two retrospec-
tive cohort studies nested in the randomized dopamine 
trial demonstrated that spontaneous donor hypother-
mia was associated with lower creatinine levels before 
organ procurement without effect on kidney graft 
survival [112], and with an unfavorable clinical course 
after heart transplant [113]. In a clinical population of 
post-cardiac arrest patients, i.e., patients at increased 
risk of hemodynamic instability, a meta-analysis of five 
clinical trials found a higher risk of recurrent arrest in 
patients with induced hypothermia (< 35 °C) in prehos-
pital management (RR 1.23; 95% CI 1.02–1.48) [114].
Remarks Hypothermia is a low-cost intervention 
[115] associated with better renal graft function, but it 
can increase the risk of cardiac arrest in the potential 
donor [111, 114]. The risk appears to be low in hemo-
dynamically stable potential donors, in whom the use 
of hypothermia can be justified by improved graft via-
bility. In the presence of hemodynamic instability [111], 
normothermia (> 35 °C) should be maintained in poten-
tial donors to reduce the risk of cardiac arrest [114]. 
Induction of moderate hypothermia (34–35 °C) is con-
sidered a simple (application of ice packs) and inex-
pensive approach, but it is important to monitor core 
temperature, which is not available in all ICUs.
Red blood cell transfusion
 18. We suggest transfusing packed red blood cells in 
potential donors with hemoglobin levels < 7  g/dL 
(very low level of evidence, weak recommenda-
tion).
Summary of evidence The systematic literature search 
identified 1 descriptive observational study that evalu-
ated function in 1884 renal grafts from 1006 brain-dead 
donors. Among donors, 52% received blood transfu-
sion. Renal grafts from transfused donors had a lower 
rate of delayed graft function than those from non-
transfused donors (26% vs. 34%, p < 0.001). The criteria 
defining the need for blood transfusion were not identi-
fied [116].
Remarks Anemia can compromise oxygen transport 
and delivery to the organs that are intended to be pre-
served for transplantation. However, we are unaware of 
the hemoglobin concentration necessary to contribute 
to adequate oxygen transport and delivery in potential 
donors. Considering the high cost and frequent shortage 
of blood products for transfusion, the decision to trans-
fuse should not differ from the usual practice in other 
critically ill patients.
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Goal‑directed protocols
 19. We suggest using a goal-directed protocol during 
the management of potential donors (very low level 
of evidence, weak recommendation).
Summary of evidence Although there is no consistent 
evidence about an individual treatment that will improve 
the number and quality of donated organs [117], obser-
vational studies have reported that combining different 
treatments through the application of a potential donor-
management protocol is associated with a higher organ 
yield for transplantation [24, 78, 118–124], lower inci-
dence of delayed renal graft function [111], greater eligi-
bility for lung donation [19, 28], and lower incidence of 
donor losses due to cardiac arrest [19, 24, 28, 119, 120]. 
In general, the outcomes are associated with the number 
of goals achieved during potential donor management, 
including ventilatory, hemodynamic, and endocrine-
metabolic management goals [24, 78, 121–123]. In seven 
studies, the use of a checklist helped implement the goal-
directed protocols and may have positively influenced the 
results [19, 28, 78, 121, 124–126].
Remarks The application of a potential donor-manage-
ment protocol guided by a clinical goal-directed checklist 
may contribute to increasing the number of organs trans-
planted per donor, influence graft function, and reduce 
donor losses due to cardiac arrest.
General considerations and future directions
The present guideline aimed to provide parameters to 
optimize the clinical management of potential donors 
based on the available evidence, aiming to improve the 
quality of organs for transplantation and to reduce donor 
losses. However, it is well known that it may take years 
for a large-scale translation of the best scientific evidence 
into effective practice. Thus, establishing clinical proto-
cols can help to reduce the time required to incorporate 
best practices. The use of a goal-directed checklist can 
play an important role in the adjustment of approaches 
and adherence to the best evidence in complex proce-
dures [127–130].
This guideline evaluated a broad volume of treatments 
and we performed rigorous PICO-driven research to 
provide the recommendations based on standardized 
rapid review methods [9, 10]. Potential limitations are 
the low or very low certainty in the evidence identified 
for many of the questions, and indirect evidence that did 
not change after the systematic review update. However, 
management recommendations are consistent with simi-
lar documents recently published [11, 131, 132].
Several challenges regarding ethical, infrastructure, and 
operational issues are faced while planning and conduct-
ing studies that involve potential organ donors, which 
results in few randomized clinical trials [133]. The scar-
city of studies with such methodological strength implies 
uncertainties about some interventions such as low-dose 
dopamine and moderate hypothermia, which, despite 
appearing to be related to renal graft benefit, may result 
in cardiac arrhythmias and hemodynamic instability. 
In this context, developing clinical trials in this field of 
medical knowledge may be helpful to understand some 
important aspects in the management of the potential 
organ donor.
Some observational studies have reported that the 
application of a checklist to guide the management of 
brain-dead potential donors may help to reduce the rate 
of cardiac arrest in potential donors and increase the 
number of organs recovered per donor [24, 78, 119, 121, 
122, 124, 126, 134, 135]. In this context, we used the main 
recommendations of the present guideline to develop an 
evidence-based clinical goal-directed checklist (Addi-
tional file  3) with the purpose of providing transplant 
coordinators and ICU professionals with essential infor-
mation to optimize the care of potential donors.
However, because the available studies highlighting 
the role of potential donor-management checklists are 
observational, there is insufficient evidence to support 
the systematic use of checklists in the management of 
potential donors. Therefore, we proposed the Donation 
Network to Optimize Organ Recovery Study (DONORS; 
NCT03179020), which is a parallel cluster randomized-
controlled multicenter trial that aims to test the effec-
tiveness of the implementation of a checklist containing 
goals and recommendations of care in reducing organ 
donor losses due to cardiac arrest and increasing the 
number of organs recovered per donor [136].
The implementation of the checklist should be pre-
ceded by the appropriate training of intensive care teams 
and transplant coordinators. We suggest applying the 
checklist at the bedside immediately after the first clinical 
examination for the diagnosis of brain death, repeating 
the application, ideally, every 6  h until organ procure-
ment for transplantation. We also suggest that a mem-
ber of the transplant coordination office or a designated 
professional of the ICU or emergency department applies 
the checklist at the bedside. The same individual will also 
be responsible for personally prompting the physician in 
charge to modify the clinical management if any inappro-
priate aspect of care, according to the checklist, is noted.
Page 11 of 15Westphal et al. Ann. Intensive Care          (2020) 10:169  
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1361 3‑020‑00787 ‑0.
Additional file 1. Working group and contributions of each participant. 
Additional file 2. Declaration of competing interests. 
Additional file 3. Checklist for clinical management of brain‑dead poten‑
tial organ donor.
Acknowledgements
The authors would like to thank the Brazilian Ministry of Health and the Gen‑
eral Coordination Office of the National Transplant System (CGSNT), as well as 
Moinhos de Vento Hospital, the Brazilian Association of Organ Transplantation 
(ABTO), the Brazilian Association of Intensive Care Medicine (AMIB) Committee 
for Organ Donation for Transplant, and the Brazilian Research in Intensive Care 
Network (BRICNet) for their support.
Authors’ contributions
All authors, except for AR, DFSP, FDP, RCM, and RRN, participated in at least one 
of the expert panels. All authors read and approved the final manuscript. The 
detailed contribution of each author is presented in Additional file 1.
Funding
This guideline was funded by the Brazilian Ministry of Health through the 
Programa de Apoio ao Desenvolvimento Institucional do Sistema Único de 
Saúde (PROADI‑SUS). The funding body has no role in the coordination of the 
guideline.
Availability of data and materials
All relevant data are within the paper and its additional files.





The competing interests of each author are presented in Additional file 2.
Author details
1 Hospital Moinhos de Vento (HMV), R. Ramiro Barcelos, 910, Porto Alegre, 
RS 90035000, Brazil. 2 Hospital Municipal São José (HMSJ), Joinville, SC, Brazil. 
3 Centro Hospitalar Unimed, Joinville, SC, Brazil. 4 Hospital do Coração (HCor), 
R. Desembargador Eliseu Guilherme, 147, São Paulo, SP 04004030, Brazil. 5 Uni‑
versidade da Região de Joinville (UNIVILLE), R. Paulo Malschitzki, 10, Joinville, 
SC 89219710, Brazil. 6 Clínica de Nefrologia de Joinville, R. Plácido Gomes, 370, 
Joinville, SC 89202‑050, Brazil. 7 Hospital de Clínicas de Porto Alegre (HCPA), 
R. Ramiro Barcelos, 2350, Porto Alegre, RS 90035007, Brazil. 8 Universidade 
Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Sarmento Leite, 245, 
Porto Alegre, RS 90050‑170, Brazil. 9 Hospital de Pronto de Socorro (HPS), Porto 
Alegre, RS, Brazil. 10 General Coordination Office of the National Transplant 
System, Brazilian Ministry of Health, Esplanada dos Ministérios, Bloco G, Edifício 
Sede, Brasília, DF 70058900, Brazil. 11 Faculdade de Medicina, Universidade 
de São Paulo (USP), Av. Dr, Arnaldo 455, Sala 3206, São Paulo, SP 01246903, 
Brazil. 12 Universidade do Extremo Sul Catarinense (UNESC), Av. Universitária, 
1105, Criciúma, SC 88806000, Brazil. 13 Intensive Care Unit, Hospital São José, 
R. Cel. Pedro Benedet, 630, Criciúma, SC 88801‑250, Brazil. 14 National Institute 
of Infectious Disease Evandro Chagas, Fundação Oswaldo Cruz (FIOCRUZ), Av. 
Brasil, 4365, Rio de Janeiro, RJ 21040360, Brazil. 15 Instituto D’Or de Pesquisa 
e Ensino (IDOR), R. Diniz Cordeiro, 30, Rio de Janeiro, RJ 22281100, Brazil. 
16 Hospital São Paulo (HU), Universidade Federal de São Paulo (UNIFESP), R. 
Napoleão de Barros 737, São Paulo, SP 04024002, Brazil. 17 Organização de 
Procura de Órgãos e Tecidos de Santa Catarina (OPO/SC), Rua Esteves Júnior, 
390, Florianópolis, SC 88015130, Brazil. 18 Hospital Sírio‑Libanês, R. Dona Adma 
Jafet, 115, São Paulo, SP, Brazil. 19 Universidade Federal do Rio Grande do Sul 
(UFRGS), Ramiro Barcelos, 2350, Porto Alegre, RS 90035007, Brazil. 20 Facul‑
dade de Medicina de São José do Rio Preto, Av Faria Lima, 5544, São José 
do Rio Preto, SP 15090000, Brazil. 21 National Institute for Health Technology 
Assessment, UFRGS, Rua Ramiro Barcelos, 2350, Porto Alegre, RS 90035903, 
Brazil. 22 Department of Health Research Methods, Evidence, and Impact (HEI), 
McMaster University, 1280 Main St W, Hamilton, ON, Canada. 
Received: 3 August 2020   Accepted: 1 December 2020
References
 1. Tullius SG, Rabb H. Improving the supply and quality of deceased‑
donor organs for transplantation. N Engl J Med. 2018;378:1920–9. https 
://doi.org/10.1056/NEJMr a1507 080.
 2. The Madrid resolution on organ donation and transplantation. national 
responsibility in meeting the needs of patients, guided by the WHO 
principles. Transplantation. 2011;91(Suppl 11):S29–31. https ://doi.
org/10.1097/01.tp.00003 99131 .74618 .a5.
 3. Dominguez‑Gil B, Delmonico FL, Shaheen FA, Matesanz R, O’Connor K, 
Minina M, et al. The critical pathway for deceased donation: report‑
able uniformity in the approach to deceased donation. Transpl Int. 
2011;24:373–8. https ://doi.org/10.1111/j.1432‑2277.2011.01243 .x.
 4. DuBose J, Salim A. Aggressive organ donor management protocol. J 
Intensive Care Med. 2008;23:367–75. https ://doi.org/10.1177/08850 
66608 32420 8.
 5. Powner D. Aggressive donor care–to what end? J Intensive Care Med. 
2008;23:409–11. https ://doi.org/10.1177/08850 66608 32419 8.
 6. Westphal GA, Caldeira Filho M, Vieira KD, Zaclikevis VR, Bartz MC, 
Wanzuita R, et al. Guidelines for potential multiple organ donors (adult): 
part I. Overview and hemodynamic support. Rev Bras Ter Intensiva. 
2011;23:255–68.
 7. Westphal GA, Caldeira Filho M, Vieira KD, Zaclikevis VR, Bartz MC, Wan‑
zuita R, et al. Guidelines for potential multiple organ donors (adult): part 
II. Mechanical ventilation, endocrine metabolic management, hemato‑
logical and infectious aspects. Rev Bras Ter Intensiva. 2011;23:269–82.
 8. Westphal GA, Caldeira Filho M, Vieira KD, Zaclikevis VR, Bartz MC, 
Wanzuita R, et al. Guidelines for potential multiple organ donors 
(adult). Part III: organ‑specific recommendations. Rev Bras Ter Intensiva. 
2011;23:410–25.
 9. Schunemann HJ, Moja L. Reviews: rapid! Rapid! Rapid!… and system‑
atic. Syst Rev. 2015;4:4. https ://doi.org/10.1186/2046‑4053‑4‑4.
 10. Haby MM, Chapman E, Clark R, Barreto J, Reveiz L, Lavis JN. Designing 
a rapid response program to support evidence‑informed decision‑
making in the Americas region: using the best available evidence and 
case studies. Implement Sci. 2016;11:117. https ://doi.org/10.1186/s1301 
2‑016‑0472‑9.
 11. Kotloff RM, Blosser S, Fulda GJ, Malinoski D, Ahya VN, Angel L, et al. 
Management of the potential organ donor in the ICU: Society of Critical 
Care Medicine/American College of Chest Physicians/Association of 
Organ Procurement Organizations Consensus Statement. Crit Care 
Med. 2015;43:1291–325. https ://doi.org/10.1097/CCM.00000 00000 
00095 8.
 12. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‑Ytter Y, Alonso‑Coello P, 
et al. GRADE: an emerging consensus on rating quality of evidence 
and strength of recommendations. BMJ. 2008;336:924–6. https ://doi.
org/10.1136/bmj.39489 .47034 7.AD.
 13. Mascia L, Zavala E, Bosma K, Pasero D, Decaroli D, Andrews P, et al. High 
tidal volume is associated with the development of acute lung injury 
after severe brain injury: an international observational study. Crit Care 
Med. 2007;35:1815–20. https ://doi.org/10.1097/01.CCM.00002 75269 
.77467 .DF.
 14. Mascia L, Pasero D, Slutsky AS, Arguis MJ, Berardino M, Grasso S, et al. 
Effect of a lung protective strategy for organ donors on eligibility and 
availability of lungs for transplantation: a randomized controlled trial. 
JAMA. 2010;304:2620–7. https ://doi.org/10.1001/jama.2010.1796.
 15. Lebovitz DJ, Reis K, Yun J, Herman L, McCurry KR. An aggressive lung 
recruitment protocol increases the percentage of lung donors with 
no increased adverse effect in lung recipients: 3173. Transplantation. 
2010;90:356.
Page 12 of 15Westphal et al. Ann. Intensive Care          (2020) 10:169 
 16. Noiseux N, Nguyen BK, Marsolais P, Dupont J, Simard L, Houde I, et al. 
Pulmonary recruitment protocol for organ donors: a new strategy to 
improve the rate of lung utilization. Transplant Proc. 2009;41:3284–9. 
https ://doi.org/10.1016/j.trans proce ed.2009.08.041.
 17. Gabbay E, Williams TJ, Griffiths AP, Macfarlane LM, Kotsimbos TC, Esmore 
DS, et al. Maximizing the utilization of donor organs offered for lung 
transplantation. Am J Respir Crit Care Med. 1999;160:265–71. https ://
doi.org/10.1164/ajrcc m.160.1.98110 17.
 18. Gattinoni L, Carlesso E, Brazzi L, Caironi P. Positive end‑expiratory 
pressure. Curr Opin Crit Care. 2010;16:39–44. https ://doi.org/10.1097/
MCC.0b013 e3283 35472 3.
 19. Minambres E, Coll E, Duerto J, Suberviola B, Mons R, Cifrian JM, et al. 
Effect of an intensive lung donor‑management protocol on lung trans‑
plantation outcomes. J Heart Lung Transplant. 2014;33:178–84. https ://
doi.org/10.1016/j.healu n.2013.10.034.
 20. Angel LF, Levine DJ, Restrepo MI, Johnson S, Sako E, Carpenter A, et al. 
Impact of a lung transplantation donor‑management protocol on 
lung donation and recipient outcomes. Am J Respir Crit Care Med. 
2006;174:710–6. https ://doi.org/10.1164/rccm.20060 3‑432OC .
 21. Writing Group for the Alveolar Recruitment for Acute Respiratory 
Distress Syndrome Trial I, Cavalcanti AB, Suzumura EA, Laranjeira LN, 
Paisani DM, Damiani LP, et al. Effect of lung recruitment and Titrated 
Positive End‑Expiratory Pressure (PEEP) vs Low PEEP on mortality in 
patients with acute respiratory distress syndrome: a randomized clinical 
trial. JAMA. 2017;318:1335–45. https ://doi.org/10.1001/jama.2017.14171 
.
 22. Gruenberger T, Steininger R, Sautner T, Mittlbock M, Muhlbacher F. Influ‑
ence of donor criteria on postoperative graft function after orthotopic 
liver transplantation. Transpl Int. 1994;7(Suppl 1):S672–4. https ://doi.
org/10.1111/j.1432‑2277.1994.tb014 70.x.
 23. delaTorre AN, Kuo PC, Plotkin JS, Ridge LA, Howell CD, Bartlett ST, et al. 
Influence of donor base deficit status on recipient outcomes in liver 
transplantation. Transplant Proc. 1997;29:474. https ://doi.org/10.1016/
s0041 ‑1345(96)00627 ‑6.
 24. Westphal GA, Coll E, deSouza RL, Wagner S, Montemezzo A, Cani 
de Souza FC, et al. Positive impact of a clinical goal‑directed proto‑
col on reducing cardiac arrests during potential brain‑dead donor 
maintenance. Crit Care. 2016;20:323. https ://doi.org/10.1186/s1305 
4‑016‑1484‑1.
 25. Murugan R, Venkataraman R, Wahed AS, Elder M, Carter M, Madden NJ, 
et al. Preload responsiveness is associated with increased interleu‑
kin‑6 and lower organ yield from brain‑dead donors. Crit Care Med. 
2009;37:2387–93. https ://doi.org/10.1097/CCM.0b013 e3181 a960d 6.
 26. Al‑Khafaji A, Elder M, Lebovitz DJ, Murugan R, Souter M, Stuart S, et al. 
Protocolized fluid therapy in brain‑dead donors: the multicenter rand‑
omized MOnIToR trial. Intensive Care Med. 2015;41:418–26. https ://doi.
org/10.1007/s0013 4‑014‑3621‑0.
 27. Abdelnour T, Rieke S. Relationship of hormonal resuscitation therapy 
and central venous pressure on increasing organs for transplant. J 
Heart Lung Transplant. 2009;28:480–5. https ://doi.org/10.1016/j.healu 
n.2009.01.018.
 28. Minambres E, Perez‑Villares JM, Chico‑Fernandez M, Zabalegui A, 
Duenas‑Jurado JM, Misis M, et al. Lung donor treatment protocol 
in brain dead‑donors: a multicenter study. J Heart Lung Transplant. 
2015;34:773–80. https ://doi.org/10.1016/j.healu n.2014.09.024.
 29. Minambres E, Perez‑Villares JM, Terceros‑Almanza L, Duenas‑Jurado JM, 
Zabalegui A, Misis M, et al. An intensive lung donor treatment protocol 
does not have negative influence on other grafts: a multicentre study. 
Eur J Cardiothorac Surg. 2016;49:1719–24. https ://doi.org/10.1093/ejcts 
/ezv45 4.
 30. Cecconi M, De Backer D, Antonelli M, Beale R, Bakker J, Hofer C, et al. 
Consensus on circulatory shock and hemodynamic monitoring. Task 
force of the European Society of Intensive Care Medicine. Intensive Care 
Med. 2014;40:1795–815. https ://doi.org/10.1007/s0013 4‑014‑3525‑z.
 31. Schnuelle P, Lorenz D, Mueller A, Trede M, Van Der Woude FJ. Donor 
catecholamine use reduces acute allograft rejection and improves graft 
survival after cadaveric renal transplantation. Kidney Int. 1999;56:738–
46. https ://doi.org/10.1046/j.1523‑1755.1999.00567 .x.
 32. Schnuelle P, Berger S, de Boer J, Persijn G, van der Woude FJ. Effects of 
catecholamine application to brain‑dead donors on graft survival in 
solid organ transplantation. Transplantation. 2001;72:455–63. https ://
doi.org/10.1097/00007 890‑20010 8150‑00017 .
 33. von Ziegler F, Helbig S, Kreissl N, Meiser B, Becker A, Kaczmarek I. 
Norepinephrine versus dopamine pretreatment of potential heart 
donors‑impact on long‑term outcome. Ann Transplant. 2013;18:320–6. 
https ://doi.org/10.12659 /AOT.88396 0.
 34. Dictus C, Vienenkoetter B, Esmaeilzadeh M, Unterberg A, Ahmadi 
R. Critical care management of potential organ donors: our current 
standard. Clin Transplant. 2009;23(Suppl 21):2–9. https ://doi.org/10.1
111/j.1399‑0012.2009.01102 .x.
 35. Wood KE, Becker BN, McCartney JG, D’Alessandro AM, Coursin DB. 
Care of the potential organ donor. N Engl J Med. 2004;351(26):2730–
9. https ://doi.org/10.1056/NEJMr a0131 03.
 36. Marik PE, Baram M, Vahid B. Does central venous pressure predict 
fluid responsiveness? A systematic review of the literature and the 
tale of seven mares. Chest. 2008;134:172–8. https ://doi.org/10.1378/
chest .07‑2331.
 37. Eskesen TG, Wetterslev M, Perner A. Systematic review including 
re‑analyses of 1148 individual data sets of central venous pressure as 
a predictor of fluid responsiveness. Intensive Care Med. 2016;42:324–
32. https ://doi.org/10.1007/s0013 4‑015‑4168‑4.
 38. Marik PE, Cavallazzi R, Vasu T, Hirani A. Dynamic changes in arterial 
waveform derived variables and fluid responsiveness in mechani‑
cally ventilated patients: a systematic review of the literature. Crit 
Care Med. 2009;37:2642–7. https ://doi.org/10.1097/CCM.0b013 e3181 
a590d a.
 39. Rui Q, Jiang Y, Chen M, Zhang N, Yang H, Zhou Y. Dopamine versus 
norepinephrine in the treatment of cardiogenic shock: a PRISMA‑
compliant meta‑analysis. Medicine. 2017;96:e8402. https ://doi.
org/10.1097/MD.00000 00000 00840 2.
 40. Benck U, Hoeger S, Brinkkoetter PT, Gottmann U, Doenmez D, 
Boesebeck D, et al. Effects of donor pre‑treatment with dopamine 
on survival after heart transplantation: a cohort study of heart 
transplant recipients nested in a randomized controlled multicenter 
trial. J Am Coll Cardiol. 2011;58:1768–77. https ://doi.org/10.1016/j.
jacc.2011.05.060.
 41. Schnuelle P, Gottmann U, Hoeger S, Boesebeck D, Lauchart W, Weiss C, 
et al. Effects of donor pretreatment with dopamine on graft function 
after kidney transplantation: a randomized controlled trial. JAMA. 
2009;302:1067–75. https ://doi.org/10.1001/jama.2009.1310.
 42. Schnuelle P, Schmitt WH, Weiss C, Habicht A, Renders L, Zeier M, 
et al. Effects of dopamine donor pretreatment on graft survival after 
kidney transplantation: a randomized trial. Clin J Am Soc Nephrol. 
2017;12:493–501. https ://doi.org/10.2215/CJN.07600 716.
 43. Benck U, Jung M, Kruger B, Grimm A, Weiss C, Yard BA, et al. Donor 
Dopamine Does Not Affect Liver Graft Survival: evidence of Safety From 
a Randomized Controlled Trial. Liver Transpl. 2018;24:1336–45. https ://
doi.org/10.1002/lt.25301 .
 44. Iwai A, Sakano T, Uenishi M, Sugimoto H, Yoshioka T, Sugimoto T. Effects 
of vasopressin and catecholamines on the maintenance of circulatory 
stability in brain‑dead patients. Transplantation. 1989;48:613–7.
 45. Kinoshita Y, Yahata K, Yoshioka T, Onishi S, Sugimoto T. Long‑term renal 
preservation after brain death maintained with vasopressin and epi‑
nephrine. Transpl Int. 1990;3:15–8. https ://doi.org/10.1007/bf003 33196 .
 46. Pennefather SH, Bullock RE, Mantle D, Dark JH. Use of low dose arginine 
vasopressin to support brain‑dead organ donors. Transplantation. 
1995;59:58–62. https ://doi.org/10.1097/00007 890‑19950 1150‑00011 .
 47. Plurad DS, Bricker S, Neville A, Bongard F, Putnam B. Arginine vasopres‑
sin significantly increases the rate of successful organ procurement in 
potential donors. Am J Surg. 2012;204:856–60. https ://doi.org/10.1016/j.
amjsu rg.2012.05.011.
 48. Chen JM, Cullinane S, Spanier TB, Artrip JH, John R, Edwards NM, et al. 
Vasopressin deficiency and pressor hypersensitivity in hemodynami‑
cally unstable organ donors. Circulation. 1999;100:244–6. https ://doi.
org/10.1161/01.cir.100.suppl _2.ii‑244.
 49. Katz K, Lawler J, Wax J, O’Connor R, Nadkarni V. Vasopressin pressor 
effects in critically ill children during evaluation for brain death and 
organ recovery. Resuscitation. 2000;47:33–40. https ://doi.org/10.1016/
s0300 ‑9572(00)00196 ‑9.
 50. Benck U, Gottmann U, Hoeger S, Lammert A, Rose D, Boesebeck D, et al. 
Donor desmopressin is associated with superior graft survival after 
Page 13 of 15Westphal et al. Ann. Intensive Care          (2020) 10:169  
kidney transplantation. Transplantation. 2011;92:1252–8. https ://doi.
org/10.1097/TP.0b013 e3182 36cd4 c.
 51. Shemie SD, Ross H, Pagliarello J, Baker AJ, Greig PD, Brand T, et al. 
Organ donor management in Canada: recommendations of the forum 
on Medical Management to Optimize Donor Organ Potential. CMAJ. 
2006;174:S13–32. https ://doi.org/10.1503/cmaj.04513 1.
 52. Gramm HJ, Meinhold H, Bickel U, Zimmermann J, von Hammerstein B, 
Keller F, et al. Acute endocrine failure after brain death? Transplantation. 
1992;54:851–7. https ://doi.org/10.1097/00007 890‑19921 1000‑00016 .
 53. Fiser DH, Jimenez JF, Wrape V, Woody R. Diabetes insipidus in 
children with brain death. Crit Care Med. 1987;15:551–3. https ://doi.
org/10.1097/00003 246‑19870 6000‑00002 .
 54. Follette DM, Rudich SM, Babcock WD. Improved oxygenation and 
increased lung donor recovery with high‑dose steroid administration 
after brain death. J Heart Lung Transplant. 1998;17:423–9. https ://doi.
org/10.1007/s8010 90000 086.
 55. Dhar R, Cotton C, Coleman J, Brockmeier D, Kappel D, Marklin G, 
et al. Comparison of high‑ and low‑dose corticosteroid regimens for 
organ donor management. J Crit Care. 2013;28(111):e1–7. https ://doi.
org/10.1007/s8010 90000 086.
 56. Jafari R, Aflatoonian R, Falak R, Pourmand G, Dehghani S, Mortazavi M, 
et al. Down‑regulation of inflammatory signaling pathways despite 
up‑regulation of Toll‑like receptors; the effects of corticosteroid therapy 
in brain‑dead kidney donors, a double‑blind, randomized, controlled 
trial. Mol Immunol. 2018;94:36–44. https ://doi.org/10.1016/j.molim 
m.2017.12.012.
 57. Dupuis S, Amiel JA, Desgroseilliers M, Williamson DR, Thiboutot Z, Serri 
K, et al. Corticosteroids in the management of brain‑dead potential 
organ donors: a systematic review. Br J Anaesth. 2014;113:346–59. https 
://doi.org/10.1093/bja/aeu15 4.
 58. Pinsard M, Ragot S, Mertes PM, Bleichner JP, Zitouni S, Cook F, et al. 
Interest of low‑dose hydrocortisone therapy during brain‑dead organ 
donor resuscitation: the CORTICOME study. Crit Care. 2014;18:R158. 
https ://doi.org/10.1186/cc139 97.
 59. Venkateswaran RV, Steeds RP, Quinn DW, Nightingale P, Wilson IC, 
Mascaro JG, et al. The haemodynamic effects of adjunctive hormone 
therapy in potential heart donors: a prospective randomized double‑
blind factorially designed controlled trial. Eur Heart J. 2009;30:1771–80. 
https ://doi.org/10.1093/eurhe artj/ehp08 6.
 60. Perez‑Blanco A, Caturla‑Such J, Canovas‑Robles J, Sanchez‑Paya J. 
Efficiency of triiodothyronine treatment on organ donor hemodynamic 
management and adenine nucleotide concentration. Intensive Care 
Med. 2005;31:943–8. https ://doi.org/10.1007/s0013 4‑005‑2662‑9.
 61. Jeevanandam V. Triiodothyronine: spectrum of use in heart transplanta‑
tion. Thyroid. 1997;7:139–45. https ://doi.org/10.1089/thy.1997.7.139.
 62. Goarin JP, Cohen S, Riou B, Jacquens Y, Guesde R, Le Bret F, et al. The 
effects of triiodothyronine on hemodynamic status and cardiac func‑
tion in potential heart donors. Anesth Analg. 1996;83:41–7. https ://doi.
org/10.1097/00000 539‑19960 7000‑00008 .
 63. Randell TT, Hockerstedt KA. Triiodothyronine treatment in brain‑dead 
multiorgan donors–a controlled study. Transplantation. 1992;54:736–8. 
https ://doi.org/10.1097/00007 890‑19921 0000‑00034 .
 64. Garcia‑Fages LC, Antolin M, Cabrer C, Talbot R, Alcaraz A, Lozano F, et al. 
Effects of substitutive triiodothyronine therapy on intracellular nucleo‑
tide levels in donor organs. Transplant Proc. 1991;23:2495–6.
 65. Mariot J, Jacob F, Voltz C, Perrier JF, Strub P. Value of hormonal treatment 
with triiodothyronine and cortisone in brain dead patients. Ann Fr 
Anesth Reanim. 1991;10:321–8. https ://doi.org/10.1007/s8010 90000 
086.
 66. Macdonald PS, Aneman A, Bhonagiri D, Jones D, O’Callaghan G, Sil‑
vester W, et al. A systematic review and meta‑analysis of clinical trials of 
thyroid hormone administration to brain dead potential organ donors. 
Crit Care Med. 2012;40:1635–44. https ://doi.org/10.1097/CCM.0b013 
e3182 416ee 7.
 67. Rech TH, Moraes RB, Crispim D, Czepielewski MA, Leitao CB. Manage‑
ment of the brain‑dead organ donor: a systematic review and meta‑
analysis. Transplantation. 2013;95:966–74. https ://doi.org/10.1097/
TP.0b013 e3182 83298 e.
 68. Dhar R, Stahlschmidt E, Marklin G. A randomized trial of intravenous 
thyroxine for brain‑dead organ donors with impaired cardiac function. 
Prog Transplant. 2020;30:48–55. https ://doi.org/10.1177/15269 24819 
89329 5.
 69. Dhar R, Stahlschmidt E, Yan Y, Marklin G. A randomized trial comparing 
triiodothyronine (T3) with thyroxine (T4) for hemodynamically unstable 
brain‑dead organ donors. Clin Transplant. 2019;33:e13486. https ://doi.
org/10.1111/ctr.13486 .
 70. Hesse UJ, Sutherland DE. Influence of serum amylase and plasma glu‑
cose levels in pancreas cadaver donors on graft function in recipients. 
Diabetes. 1989;38(Suppl 1):1–3. https ://doi.org/10.2337/diab.38.1.s1.
 71. Gores PF, Gillingham KJ, Dunn DL, Moudry‑Munns KC, Najarian JS, 
Sutherland DE. Donor hyperglycemia as a minor risk factor and 
immunologic variables as major risk factors for pancreas allograft loss 
in a multivariate analysis of a single institution’s experience. Ann Surg. 
1992;215:217–30. https ://doi.org/10.1097/00000 658‑19920 3000‑00005 .
 72. Masson F, Thicoipe M, Gin H, de Mascarel A, Angibeau RM, Favarel‑
Garrigues JF, et al. The endocrine pancreas in brain‑dead donors. A 
prospective study in 25 patients. Transplantation. 1993;56:363–7. https 
://doi.org/10.1097/00007 890‑19930 8000‑00022 .
 73. Odorico JS, Heisey DM, Voss BJ, Steiner DS, Knechtle SJ, D’Alessandro 
AM, et al. Donor factors affecting outcome after pancreas transplanta‑
tion. Transplant Proc. 1998;30:276–7. https ://doi.org/10.1016/s0041 
‑1345(97)01263 ‑3.
 74. Shaffer D, Madras PN, Sahyoun AI, Simpson MA, Monaco AP. Cadaver 
donor hyperglycemia does not impair long‑term pancreas allograft 
survival or function. Transplant Proc. 1994;26:439–40.
 75. Blasi‑Ibanez A, Hirose R, Feiner J, Freise C, Stock PG, Roberts JP, et al. 
Predictors associated with terminal renal function in deceased organ 
donors in the intensive care unit. Anesthesiology. 2009;110:333–41. 
https ://doi.org/10.1097/ALN.0b013 e3181 94ca8 a.
 76. Perez‑Protto SE, Reynolds LF, Dalton JE, Taketomi T, Irefin SA, Parker BM, 
et al. Deceased donor hyperglycemia and liver graft dysfunction. Prog 
Transplant. 2014;24:106–12. https ://doi.org/10.7182/pit20 14737 .
 77. Sally MB, Ewing T, Crutchfield M, Patel MS, Raza S, DeLaCruz S, et al. 
Determining optimal threshold for glucose control in organ donors 
after neurologic determination of death: a United Network for Organ 
Sharing Region 5 Donor Management Goals Workgroup prospec‑
tive analysis. J Trauma Acute Care Surg. 2014;76:62–8. https ://doi.
org/10.1097/ta.0b013 e3182 ab0d9 b.
 78. Patel MS, Zatarain J, De La Cruz S, Sally MB, Ewing T, Crutchfield M, et al. 
The impact of meeting donor management goals on the number of 
organs transplanted per expanded criteria donor: a prospective study 
from the UNOS Region 5 Donor Management Goals Workgroup. JAMA 
Surg. 2014;149:969–75. https ://doi.org/10.1001/jamas urg.2014.967.
 79. Khosravi MB, Firoozifar M, Ghaffaripour S, Sahmeddini MA, Eghbal MH. 
Early outcomes of liver transplants in patients receiving organs from 
hypernatremic donors. Exp Clin Transplant. 2013;11:537–40. https ://doi.
org/10.6002/ect.2012.0274.
 80. Kaseje N, McLin V, Toso C, Poncet A, Wildhaber BE. Donor hypernatremia 
before procurement and early outcomes following pediatric liver 
transplantation. Liver Transpl. 2015;21:1076–81. https ://doi.org/10.1002/
lt.24145 .
 81. Mangus RS, Fridell JA, Vianna RM, Milgrom ML, Chestovich P, Vanden‑
boom C, et al. Severe hypernatremia in deceased liver donors does 
not impact early transplant outcome. Transplantation. 2010;90:438–43. 
https ://doi.org/10.1097/TP.0b013 e3181 e764c 0.
 82. Kaczmarek I, Tenderich G, Groetzner J, Deutsch MA, Schulz U, Beiras‑
Fernandez A, et al. The controversy of donor serum sodium levels in 
heart transplantation ‑ a multicenter experience. Thorac Cardiovasc 
Surg. 2006;54:313–6. https ://doi.org/10.1055/s‑2006‑92388 9.
 83. Totsuka E, Dodson F, Urakami A, Moras N, Ishii T, Lee MC, et al. Influence 
of high donor serum sodium levels on early postoperative graft func‑
tion in human liver transplantation: effect of correction of donor hyper‑
natremia. Liver Transpl Surg. 1999;5:421–8. https ://doi.org/10.1002/
lt.50005 0510.
 84. Dawwas MF, Lewsey JD, Neuberger JM, Gimson AE. The impact of 
serum sodium concentration on mortality after liver transplantation: a 
cohort multicenter study. Liver Transpl. 2007;13:1115–24. https ://doi.
org/10.1002/lt.21154 .
 85. Cywinski JB, Mascha E, Miller C, Eghtesad B, Nakagawa S, Vincent JP, 
et al. Association between donor‑recipient serum sodium differences 
Page 14 of 15Westphal et al. Ann. Intensive Care          (2020) 10:169 
and orthotopic liver transplant graft function. Liver Transpl. 2008;14:59–
65. https ://doi.org/10.1002/lt.21305 .
 86. Mousavi SA, Shahabi S, Mostafapour E, Purfakharan M, Fereshteh‑
nejad SM, Amini J, et al. Comparison of the serum electrolyte levels 
among patients died and survived in the intensive care unit. Tanaffos. 
2012;11:36–42.
 87. Chen M, Sun R, Hu B. The influence of serum magnesium level 
on the prognosis of critically ill patients. Zhonghua Wei Zhong 
Bing Ji Jiu Yi Xue. 2015;27:213–7. https ://doi.org/10.3760/cma.j.i
ssn.2095‑4352.2015.03.011.
 88. Kumar S, Honmode A, Jain S, Bhagat V. Does magnesium matter in 
patients of Medical Intensive Care Unit: a study in rural Central India. 
Indian J Crit Care Med. 2015;19:379–83. https ://doi.org/10.4103/0972‑
5229.16027 2.
 89. Velissaris D, Karamouzos V, Pierrakos C, Aretha D, Karanikolas M. 
Hypomagnesemia in critically ill sepsis patients. J Clin Med Res. 
2015;7:911–8. https ://doi.org/10.14740 /jocmr 2351w .
 90. Thel MC, Armstrong AL, McNulty SE, Califf RM, O’Connor CM. Ran‑
domised trial of magnesium in in‑hospital cardiac arrest. Duke Internal 
Medicine Housestaff. Lancet. 1997;350:1272–6. https ://doi.org/10.1016/
s0140 ‑6736(97)05048 ‑4.
 91. Smith LF, Heagerty AM, Bing RF, Barnett DB. Intravenous infusion of 
magnesium sulphate after acute myocardial infarction: effects on 
arrhythmias and mortality. Int J Cardiol. 1986;12:175–83. https ://doi.
org/10.1016/0167‑5273(86)90239 ‑1.
 92. Alves SC, Tomasi CD, Constantino L, Giombelli V, Candal R, Bristot Mde L, 
et al. Hypomagnesemia as a risk factor for the non‑recovery of the renal 
function in critically ill patients with acute kidney injury. Nephrol Dial 
Transplant. 2013;28:910–6. https ://doi.org/10.1093/ndt/gfs26 8.
 93. Powner DJ. Factors during donor care that may affect liver transplanta‑
tion outcome. Prog Transplant. 2004;14:241–7. https ://doi.org/10.7182/
prtr.14.3.d36p8 205k2 02527 4.
 94. Adam R, Reynes M, Bao YM, Astarcioglu I, Azoulay D, Chiche L, et al. 
Impact of glycogen content of the donor liver in clinical liver transplan‑
tation. Transplant Proc. 1993;25:1536–7.
 95. Powner DJ, Bernstein IM. Extended somatic support for pregnant 
women after brain death. Crit Care Med. 2003;31:1241–9. https ://doi.
org/10.1097/01.CCM.00000 59643 .45027 .96.
 96. Dominguez‑Roldan JM, Murillo‑Cabezas F, Santamaria‑Mifsut JL, 
Munoz‑Sanchez A, Villen‑Nieto J, Barrera‑Chacon JM. Changes in resting 
energy expenditure after development of brain death. Transplant Proc. 
1995;27:2397–8.
 97. Little DM, Farrell JG, Cunningham PM, Hickey DP. Donor sepsis is not 
a contraindication to cadaveric organ donation. QJM. 1997;90:641–2. 
https ://doi.org/10.1093/qjmed /90.10.641.
 98. Zibari GB, Lipka J, Zizzi H, Abreo KD, Jacobbi L, McDonald JC. The use 
of contaminated donor organs in transplantation. Clin Transplant. 
2000;14:397–400. https ://doi.org/10.1034/j.1399‑0012.2000.14040 702.x.
 99. Lumbreras C, Sanz F, Gonzalez A, Perez G, Ramos MJ, Aguado JM, et al. 
Clinical significance of donor‑unrecognized bacteremia in the outcome 
of solid‑organ transplant recipients. Clin Infect Dis. 2001;33:722–6. https 
://doi.org/10.1086/32259 9.
 100. Caballero F, Lopez‑Navidad A, Perea M, Cabrer C, Guirado L, Sola R. 
Successful liver and kidney transplantation from cadaveric donors with 
left‑sided bacterial endocarditis. Am J Transplant. 2005;5:781–7. https ://
doi.org/10.1111/j.1600‑6143.2005.00773 .x.
 101. Len O, Gavalda J, Blanes M, Montejo M, San Juan R, Moreno A, 
et al. Donor infection and transmission to the recipient of a solid 
allograft. Am J Transplant. 2008;8:2420–5. https ://doi.org/10.111
1/j.1600‑6143.2008.02397 .x.
 102. Sozen H, Fidan K, Mahli A, Singin E, Buyan N, Sindel S, et al. Successful 
solid organ transplantation from septicemic cadaveric donors: case 
report. Transplant Proc. 2008;40:299–301. https ://doi.org/10.1016/j.trans 
proce ed.2007.11.044.
 103. Lin TL, Kuo SC, Yeh CH, Chan YC, Lin YH, Li WF, et al. Donor‑transmitted 
bacterial infection in deceased donor liver transplantation: experience 
of Southern Taiwan Medical Center. Transplant Proc. 2018;50:2711–4. 
https ://doi.org/10.1016/j.trans proce ed.2018.04.017.
 104. Corman Dincer P, Tore Altun G, Birtan D, Arslantas R, Sarici Mert N, 
Ozdemir I, et al. Incidence and risk factors for systemic infection 
in deceased donors. Transplant Proc. 2019;51:2195–7. https ://doi.
org/10.1016/j.trans proce ed.2019.03.054.
 105. Kubak BM, Gregson AL, Pegues DA, Leibowitz MR, Carlson M, Marelli 
D, et al. Use of hearts transplanted from donors with severe sepsis and 
infectious deaths. J Heart Lung Transplant. 2009;28:260–5. https ://doi.
org/10.1016/j.healu n.2008.11.911.
 106. Outerelo C, Gouveia R, Mateus A, Cruz P, Oliveira C, Ramos A. Infected 
donors in renal transplantation: expanding the donor pool. Trans‑
plant Proc. 2013;45:1054–6. https ://doi.org/10.1016/j.trans proce 
ed.2013.02.014.
 107. Freeman RB, Giatras I, Falagas ME, Supran S, O’Connor K, Bradley J, 
et al. Outcome of transplantation of organs procured from bac‑
teremic donors. Transplantation. 1999;68:1107–11. https ://doi.
org/10.1097/00007 890‑19991 0270‑00008 .
 108. Cerutti E, Stratta C, Romagnoli R, Serra R, Lepore M, Fop F, et al. Bacte‑
rial‑ and fungal‑positive cultures in organ donors: clinical impact in liver 
transplantation. Liver Transpl. 2006;12:1253–9. https ://doi.org/10.1002/
lt.20811 .
 109. Angelis M, Cooper JT, Freeman RB. Impact of donor infections on out‑
come of orthotopic liver transplantation. Liver Transpl. 2003;9:451–62. 
https ://doi.org/10.1053/jlts.2003.50094 .
 110. Ruiz I, Gavalda J, Monforte V, Len O, Roman A, Bravo C, et al. Donor‑to‑
host transmission of bacterial and fungal infections in lung trans‑
plantation. Am J Transplant. 2006;6:178–82. https ://doi.org/10.111
1/j.1600‑6143.2005.01145 .x.
 111. Niemann CU, Feiner J, Swain S, Bunting S, Friedman M, Crutchfield M, 
et al. Therapeutic hypothermia in deceased organ donors and kidney‑
graft function. N Engl J Med. 2015;373:405–14. https ://doi.org/10.1056/
NEJMo a1501 969.
 112. Schnuelle P, Mundt HM, Druschler F, Schmitt WH, Yard BA, Kramer BK, 
et al. Impact of spontaneous donor hypothermia on graft outcomes 
after kidney transplantation. Am J Transplant. 2018;18:704–14. https ://
doi.org/10.1111/ajt.14541 .
 113. Schnuelle P, Benck U, Kramer BK, Yard BA, Zuckermann A, Wagner F, 
et al. Impact of donor core body temperature on graft survival after 
heart transplantation. Transplantation. 2018;102:1891–900. https ://doi.
org/10.1097/TP.00000 00000 00233 7.
 114. Huang FY, Huang BT, Wang PJ, Zuo ZL, Heng Y, Xia TL, et al. The efficacy 
and safety of prehospital therapeutic hypothermia in patients with 
out‑of‑hospital cardiac arrest: a systematic review and meta‑analysis. 
Resuscitation. 2015;96:170–9. https ://doi.org/10.1016/j.resus citat 
ion.2015.08.005.
 115. Axelrod DA, Malinoski D, Patel MS, Broglio K, Lewis R, Groat T, et al. Mod‑
eling the economic benefit of targeted mild hypothermia in deceased 
donor kidney transplantation. Clin Transplant. 2019;33:e13626. https ://
doi.org/10.1111/ctr.13626 .
 116. de la Cruz JS, Sally MB, Zatarain JR, Crutchfield M, Ramsey K, Nielsen J, 
et al. The impact of blood transfusions in deceased organ donors on 
the outcomes of 1884 renal grafts from United Network for Organ Shar‑
ing Region 5. J Trauma Acute Care Surg. 2015;79:S164–70. https ://doi.
org/10.1097/TA.00000 00000 00067 0.
 117. van Erp AC, van Dullemen LFA, Ploeg RJ, Leuvenink HGD. Systematic 
review on the treatment of deceased organ donors. Transplant Rev 
(Orlando). 2018;32:194–206. https ://doi.org/10.1016/j.trre.2018.06.001.
 118. Rosendale JD, Chabalewski FL, McBride MA, Garrity ER, Rosengard 
BR, Delmonico FL, et al. Increased transplanted organs from the use 
of a standardized donor management protocol. Am J Transplant. 
2002;2:761–8. https ://doi.org/10.1034/j.1600‑6143.2002.20810 .x.
 119. Salim A, Velmahos GC, Brown C, Belzberg H, Demetriades D. Aggressive 
organ donor management significantly increases the number of organs 
available for transplantation. J Trauma. 2005;58:991–4. https ://doi.
org/10.1097/01.ta.00001 68708 .78049 .32.
 120. Salim A, Martin M, Brown C, Rhee P, Demetriades D, Belzberg H. The 
effect of a protocol of aggressive donor management: implications for 
the national organ donor shortage. J Trauma. 2006;61:429–33. https ://
doi.org/10.1097/01.ta.00002 28968 .63652 .c1.
 121. Malinoski DJ, Daly MC, Patel MS, Oley‑Graybill C, Foster CE, Salim A. 
Achieving donor management goals before deceased donor procure‑
ment is associated with more organs transplanted per donor. J Trauma. 
2011;71:990–5. https ://doi.org/10.1097/ta.0b013 e3182 2779e 5.
Page 15 of 15Westphal et al. Ann. Intensive Care          (2020) 10:169  
 122. Malinoski DJ, Patel MS, Daly MC, Oley‑Graybill C, Salim A, workgroup 
URD. The impact of meeting donor management goals on the number 
of organs transplanted per donor: results from the United Network for 
Organ Sharing Region 5 prospective donor management goals study. 
Crit Care Med. 2012;40:2773–80. https ://doi.org/10.1097/ccm.0b013 
e3182 5b252 a.
 123. Marshall GR, Mangus RS, Powelson JA, Fridell JA, Kubal CA, Tector AJ. 
Donor management parameters and organ yield: single center results. J 
Surg Res. 2014;191:208–13. https ://doi.org/10.1016/j.jss.2014.02.054.
 124. Patel MS, De La Cruz S, Sally MB, Groat T, Malinoski DJ. Active donor 
management during the hospital phase of care is associated with more 
organs transplanted per donor. J Am Coll Surg. 2017;225:525–31. https 
://doi.org/10.1016/j.jamco llsur g.2017.06.014.
 125. Malinoski DJ, Patel MS, Ahmed O, Daly MC, Mooney S, Graybill CO, et al. 
The impact of meeting donor management goals on the develop‑
ment of delayed graft function in kidney transplant recipients. Am J 
Transplant. 2013;13:993–1000. https ://doi.org/10.1111/ajt.12090 .
 126. Westphal GA, Zaclikevis VR, Vieira KD, Cordeiro Rde B, Horner MB, 
Oliveira TP, et al. A managed protocol for treatment of deceased 
potential donors reduces the incidence of cardiac arrest before organ 
explant. Rev Bras Ter Intensiva. 2012;24:334–40. https ://doi.org/10.1590/
s0103 ‑507x2 01200 04000 07.
 127. Haynes AB, Weiser TG, Berry WR, Lipsitz SR, Breizat AH, Dellinger EP, et al. 
A surgical safety checklist to reduce morbidity and mortality in a global 
population. N Engl J Med. 2009;360:491–9. https ://doi.org/10.1056/
NEJMs a0810 119.
 128. Pronovost P, Needham D, Berenholtz S, Sinopoli D, Chu H, Cosgrove 
S, et al. An intervention to decrease catheter‑related bloodstream 
infections in the ICU. N Engl J Med. 2006;355:2725–32. https ://doi.
org/10.1056/NEJMo a0611 15.
 129. Weiss CH, Moazed F, McEvoy CA, Singer BD, Szleifer I, Amaral LA, et al. 
Prompting physicians to address a daily checklist and process of care 
and clinical outcomes: a single‑site study. Am J Respir Crit Care Med. 
2011;184:680–6. https ://doi.org/10.1164/rccm.20110 1‑0037O C.
 130. Writing Group for the C‑ICUI, the Brazilian Research in Intensive Care, 
Cavalcanti AB, Bozza FA, Machado FR, Salluh JI, et al. Effect of a quality 
improvement intervention with daily round checklists, goal setting, 
and clinician prompting on mortality of critically ill patients: a rand‑
omized clinical trial. JAMA. 2016;315:1480–90. https ://doi.org/10.1001/
jama.2016.3463.
 131. Ball IM, Hornby L, Rochwerg B, Weiss MJ, Gillrie C, Chasse M, et al. Man‑
agement of the neurologically deceased organ donor: a Canadian clini‑
cal practice guideline. CMAJ. 2020;192:E361–9. https ://doi.org/10.1503/
cmaj.19063 1.
 132. Meyfroidt G, Gunst J, Martin‑Loeches I, Smith M, Robba C, Taccone FS, 
et al. Management of the brain‑dead donor in the ICU: general and 
specific therapy to improve transplantable organ quality. Intensive Care 
Med. 2019;45:343–53. https ://doi.org/10.1007/s0013 4‑019‑05551 ‑y.
 133. National Academies of Sciences, Engineering, and Medicine. Opportu‑
nities for organ donor intervention research: Saving lives by improving 
the quality and quantity of organs for transplantation. Washington: The 
National Academies Press; 2017.
 134. Helms AK, Torbey MT, Hacein‑Bey L, Chyba C, Varelas PN. Standardized 
protocols increase organ and tissue donation rates in the neurocriti‑
cal care unit. Neurology. 2004;63:1955–7. https ://doi.org/10.1212/01.
wnl.00001 44197 .06562 .24.
 135. Franklin GA, Santos AP, Smith JW, Galbraith S, Harbrecht BG, Garrison 
RN. Optimization of donor management goals yields increased organ 
use. Am Surg. 2010;76:587–94.
 136. Westphal GA, Robinson CC, Biasi A, Machado FR, Rosa RG, Teixeira C, 
et al. DONORS (Donation Network to Optimise Organ Recovery Study): 
Study protocol to evaluate the implementation of an evidence‑based 
checklist for brain‑dead potential organ donor management in inten‑
sive care units, a cluster randomised trial. BMJ Open. 2019;9:e028570. 
https ://doi.org/10.1136/bmjop en‑2018‑02857 0.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
